We previously reported that L-arginine infusion increased pial vessel diameter by nitric oxidedependent mechanisms, improved regional cerebral blood flow (rCBF) distal to middle cerebral artery (MCA) occlusion, and reduced infarction volume in spontaneously hypertensive rats when administered intraperitoneally before and after MCA occlusion. In this report we extend our findings (1) by examining the time course of L-arginine on rCBF and pial vessel diameter under basal conditions and on rCBF after MCA occlusion and (2) by reproducing the protective effect of L-arginine on infarct volume when given intravenously immediately after the onset of MCA occlusion in both normotensive and hypertensive models of focal cerebral ischemia.
T he semiessential amino acid L-arginine is a precursor for nitric oxide (NO), a potent vasodilator in a number of vascular beds. 1 NO has been implicated in the pathophysiology of cerebral ischemia 2 because it relaxes vascular smooth muscle, prevents platelet aggregation, 3 and contributes to toxicity induced by /V-methyl-D-aspartate (NMDA) receptor activation. 4 Measures to reduce the availability of NO in cell culture decrease NMDA-mediated cell death. In some 315 but not other 7 -8 studies, NO synthase inhibition reduces infarct volume after middle cerebral artery (MCA) occlusion. The explanation for the discrepancies remains obscure, and this has been reviewed recently.
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before and after MCA occlusion 9 and suggested that L-arginine-induced increases in regional cerebral blood flow (rCBF) mediate the response. 10 In this report, we extend our experience on the effects of infusing L-arginine by documenting (1) blood flow and pial vessel diameter changes in normal brain with time, (2) timedependent rCBF changes within marginally perfused tissue, and (3) infarction volume when the amino acid is administered intravenously and after MCA occlusion. Our data support the conclusion that exogenous L-arginine promotes the synthesis of NO or an NO-like compound that promotes vasodilation and increases rCBF and that these changes promote the reduction in infarction volume when the amino acid is administered after MCA occlusion. experiments, (1) rats were intubated either transorally or through tracheostomy and ventilated to maintain normal arterial blood gases, (2) the right femoral artery was cannulated for continuous arterial blood pressure monitoring and to obtain measurements of pHa, Paco^, Pao?, hematocrit, and plasma glucose, (3) the right femoral vein was cannulated for drug infusion, and (4) body temperature was monitored by rectal probe and maintained at 37°C by a Homeothermic Blanket Control Unit (Harvard Apparatus).
Closed Cranial Window
Male S-D rats (weight, 280 to 340 g) were anesthetized (sodium pentobarbital, 50 mg/kg IP supplemented by 10 mg/kg IP every hour), paralyzed (pancuronium bromide 0.5 to 1.0 mg IV), and ventilated with O 2 -supplemented room air. End-tidal Pco 2 was monitored continuously (Novametrix Medical Systems, Wallingford, Ct) and kept within the normocapnic range.
A closed cranial window was placed over the parietal cortex as described previously.
11 ' 12 A linear midline incision was made that exposed the skull from the occiput to the forehead. A left craniotomy (7x5 mm) was drilled using extreme care, after which the dura was incised and reflected. A metallic window (12.5 mm in diameter) equipped with three ports was placed over the exposed brain surface. Pial vessels (15 to 86 fim) were visualized using an intravital microscope (magnification x200; Leitz, Germany). A television camera (Dage MTI Inc, CCD-72 series, Michigan City, Ind) attached to the microscope transposed the picture onto a video monitor (Dage MTI Inc). Vessel diameters were measured using a video system (VIA-100, Boeckler Instruments).
Protocol
Baseline measurements were obtained after 30 minutes of equilibration. L-Arginine (3 [n=3] , 30 [n=5], or 300 [n=5] mg/kg) or D-arginine (300 mg/kg, n=4) was infused intravenously over 10 minutes, and diameters were recorded every 10 minutes for a total of 90 minutes. Changes in vessel caliber were expressed as percentage of baseline diameter. In separate groups of animals, the NO synthase inhibitor L-nitroarginine-methyl ester (L-NAME [Sigma Chemical Co, St Louis, Mo]; 1 jtm in mock CSF) was superfused under the window 20 minutes before L-arginine infusion (30 [n=3] and 300 [n=4] mg/kg).
Laser-Doppler Flowmetry. Normal Regional Cerebral Blood Flow
Male S-D rats were anesthetized with sodium pentobarbital as described above and were prepared for laser-Doppler flowmetry recording as described below. rCBF was monitored over the left parietal cortex (2 to 6 mm caudal from bregma and 2 to 6 mm from midline) in the same location as the pial vessels observed through the closed cranial window. However, probe placement over identifiable surface vessels was avoided. Measurements were made after L-arginine or saline infusion and expressed as percentage of baseline.
Protocol
L-Arginine (300 mg/kg, n=6) or a comparable volume of saline (n=7) was infused intravenously over 10 minutes. rCBF was recorded for 70 minutes. 
Laser-Doppler Flowmetry During Ischemia
Male SHR were anesthetized with halothane (3% for induction and 1% for maintenance) plus 70% nitrous oxide/balance oxygen. Animals were placed in a stereotaxic frame, and a craniotomy (4 to 6 mm lateral and -2 mm to 1 mm rostral to bregma) was made within the MCA territory, which corresponds to a transitional zone between severely ischemic and mildly ischemic tissue. 13 A paper-thin layer of the calvarium was left in place, thus avoiding epidural bleeding. The recording probe (0.8 mm in diameter, P-433) attached to a laserDoppler flowmeter (BPM 403A, TSI Inc) was steadily advanced under stereotaxic control perpendicular to the cortical surface and away from large pial vessels. The probe touched but did not indent the surface. 14 Focal cerebral ischemia was accomplished by tandem right common carotid artery (CCA)/MCA occlusion after the application of a snare ligature and clip, respectively. 
Infarct Volume
Infarct volume was determined 24 hours after occlusion of either the proximal or distal MCA. In model 1, the right distal MCA plus ipsilateral CCA was occluded (tandem CCA/MCA occlusion) in SHR. 13 In model 2, the right proximal MCA was occluded 16 in S-D rats. Anesthesia was induced and maintained by halothane, 3% and 1%, respectively, plus 70% NO/balance oxygen. Blood pressure, arterial blood gases, and body temperature were monitored as described above. Models 1 and 2 were performed by separate investigators.
To occlude the MCA at its proximal or distal segments, the vessel was exposed as follows.' 4 -' 6 A 1-cm skin incision was placed approximately midway between the right outer canthus and anterior pinna. Temporalis muscle was incised and retracted to expose the squamous bone (distal) or the infratemporal fossa (proximal). A craniotomy (3 mm in diameter) was created at the juncture of the zygoma and squamous bone (distal) or just anterior to the foramen ovale (proximal). The dura mater was opened with a fine curved needle. The MCA was occluded either by double ligation (10-0 monofilament) or by electrocauterization of the artery followed by transection. In model 1, the right CCA was ligated (4-0 silk) just before MCA occlusion. After surgery, the rats were returned to their cages, allowed free access to food and water, and given a single injection of cefazolin, 50 mg IM. The rats were killed by decapitation 24 hours later.
To measure infarct volume, brains were removed and placed in ice-cold saline for 10 minutes and sectioned coronally into seven 2-mm slices in a rodent brain matrix. Slices were placed in 2% 2,3,5 -triphenyltetrazolium chloride monohydrate (Sigma) at room temperature for 30 minutes, followed by 10% formalin overnight.
14 The area of infarction, outlined in white, was measured (Bioquant IV image analysis system) on the posterior surface of each section, and infarct volume was calculated by numeric integration of the sequential areas.
Protocol
Rats received L-arginine (300 mg/kg) by intravenous infusion over 10 minutes beginning 5 minutes after MCA occlusion and again intraperitonealry 1 hour after MCA occlusion. Values are mean±SEM. There were no significant Intergroup differences in these physiological variables In either model. SHR Indicates spontaneously hypertensive rats; S-D, Sprague-Dawley; MABP, mean arterial blood pressure; Hct, hematocrtt; GLU, plasma glucose; and BT, body temperature.
L-Arginine or D-arginine hydrochloride (Sigma) was dissolved in distilled water and adjusted to pH 7.0 with sodium hydroxide.
Results
Physiological variables for each experiment are shown in Tables 1 through 4 . There were no within-group differences (over time) nor between-group differences in mean arterial blood pressure, Paco2, PaO2, or pH in these experiments. No significant changes in rectal temperature, systemic mean arterial blood pressure, or arterial blood gases were noted in any of the experimental animals after infusion of L-or D-arginine.
Pial Vessel Diameter in Normotensive Sprague-Dawley Rats
Baseline vessel diameters were comparable for the groups receiving 3, 30, or 300 mg/kg of L-arginine or 300 mg/kg of D-arginine (43±3, 49±4, 40±4, and 44±1 fim, respectively). L-Arginine, 30 and 300 mg/kg, increased pial vessel diameter significantly, reaching a maximum of 121 ±6% of baseline. Pial vessel diameter increased shortly after infusion but became significant 20 minutes after infusion in both groups and was sustained throughout the 90-minute observation period (Fig 1) . A lower dose of L-arginine (3 mg/kg) or D-arginine (300 mg/kg) did not dilate pial vessels.
Baseline diameters for the groups receiving L-arginine with or without L-NAME were comparable (36±5 and 40±5 ^tm for 30 and 300 mg/kg L-arginine plus L-NAME groups, respectively). L-NAME (1 ^tmol/L) supervision did not affect vessel diameter (35 ±5 and 40±5 jum for 30 and 300 mg/kg L-arginine plus L-NAME groups, respectively). When measured 30 minutes after L-arginine infusion, L-NAME (1 jtmol/L) attenuated the dilator response from 115 ±3% to 104±2% (30 mg/kg) and from 115±4% to 106±2% (300 mg/kg) (Fig 2) .
Regional Cerebral Blood Flow in Normotensive Sprague-Dawley Rats
L-Arginine (300 mg/kg IV) infusion increased rCBF in left parietal cortex in S-D rats, and the effect was sustained for the 70-minute duration of recording (Fig  3) . The maximum response, achieved 10 minutes after starting infusion, reached 120±3% of baseline. Lower dosages were not tested.
Regional Cerebral Blood Flow During Focal Ischemia
Regional cerebral blood flow immediately after CCA/ MCA occlusion was 20±5, 18±3, 20±5, 22±3, and 21 ±5% of preischemic rCBF for saline, 3, 30, and 300 mg/kg of L-arginine, and 300 mg/kg of D-arginine, respectively. These reductions in dorsolateral cortex are comparable to published data after tandem CCA/MCA occlusion. 13 After L-arginine infusion, blood flow increased. A significant overall difference among groups was detected by repeated-measures ANOVA with baseline as a covariate (P=.O3). Significant differences were determined between saline and 30 mg/kg L-arginine (P<.01) and between saline and 300 mg/kg L-arginine (P=.0l) by Fisher's protected least-squares difference test. Although the increased rCBF after L-arginine was sustained for the entire recording period, there were no further changes after the first 10 minutes (Fig 4) .
Infarct Volume
Treatment initiated 5 minutes after occlusion decreased infarct volume by 35% in normotensive S-D rats subjected to proximal MCA occlusion and by 28% in SHR with tandem MCA/CCA occlusion. The infarct volumes were 154+9 mm 3 (n = 12; SHR) and 231±13 mm 3 (n=17; S-D) for the saline-treated control groups and were 111 ± 12 mm 3 (n = 10; Z^.05) and 150±12mm ministering the amino acid during the entire recording period.
The importance of blood flow to tissue survival is underscored by preliminary data showing that L-arginine-induced flow changes are accompanied by recovery in electrocortigram activity. 18 This recovery, detected by a glass microelectrode placed in cortical gray matter below the laser flow probe, followed shortly after blood flow increases (5 minutes) within the ischemic penumbra to approximately 30%. In this paradigm, increases in blood flow always anticipated recovery in the amplitude of the near-silent electroencephalogram and never vice versa. Hence, the effects of L-arginine on functional recovery are probably mediated via flow for the entire observation period. A possible role for NO was suggested by the potency of the L-but not the D-amino acid isomer (Fig 1) and by the inhibition of the vasodilator response by L-NAME (Fig 2) . We speculate that the sustained effects of a 10-minute infusion relate to continued NO production from L-arginine sequestered in endothelial cells, and/or perhaps NO sequestered in plasma combined to proteins as an 5-nitroso adduct. 17 Significant decreases in infarction size were also demonstrated after intravenously administered L-arginine by two independent investigators in both hypertensive and normotensive models of focal ischemia. These findings extend our previously published work documenting that intraperitoneally administered amino acid decreases infarction size when administered before and after MCA occlusion.
Consistent with findings in normal brain, the rCBF response to L-arginine was present in ischemic brain distal to an occluded MCA. Flow increases were observed within 10 minutes after MCA occlusion and sustained for the full 105 minutes of recording. In these experiments, rCBF increased within dorsolateral cortex from approximately 20% to values of approximately 30% of baseline. We did not observe decreases or increases in systemic arterial blood pressure after ad-
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Fra 4. Bar graph shows that L-arginine 30 mg/kg IV (coarsehatched column, n=6) or 300 mg/kg IV (fine-hatched column, n=12) increases regional cerebral blood flow (rCBF) within dorsolateral ischemic cortex during middle cerebral artery (MCA) occlusion in spontaneously hypertensive rats compared with saline (filled column, n=6). The Infusion continued for 10 minutes and began 5 minutes after MCA occlusion. One hundred percent rCBF refers to rCBF Just after the onset of MCA occtuslon and was approximately 20% of the preischemic value. Significant increases in rCBF were not observed after L-arginine 3 mg/kg (open column, n=4) or D-arginine 300 mg/kg (crosshatched column, n»6). Error bars denote SEM. increases and not via direct effects on tissue metabolism. Preliminary findings using dynamic susceptibility contrast magnetic resonance imaging are in agreement with the above. 19 In those experiments, L-arginine infusion was accompanied by increases in indexes of both cerebral blood volume and flow within the ischemic SHR brain after MCA/CCA occlusion as well as by an apparent decrease in the volume of unperfused tissue.
We remain intrigued by the apparent specificity of the response to the cerebrovasculature (at the dosages tested) and by the suggestion that within this compartment, NO synthase remains unsaturated with substrate. 10 Indeed, in most tissues including brain, NO synthase is reportedly saturated. Intracellular free L-arginine levels are approximately 300 to 800 ^imol/L, 20 -21 whereas the K m for substrate is approximately 2.9^ and 2 jtmol/L 23 within bovine aortic endothelial and rat cerebellar cells, respectively. Free L-arginine levels may be more difficult to assess within component cells of brain because glia tend to sequester the amino acid, 24 and endothelial cells possess a selective uptake and transport mechanism. 25 We believe that blood vessels remain the most likely site for the conversion of L-arginine because (1) pial vessel dilation can be blocked by topical L-NAME at concentrations and time intervals that are insufficient to reduce tissue NO synthase activity, 26 (2) L-arginine may not accumulate within brain at early time points because it does not readily cross the blood-brain barrier, and (3) the L-arginine-induced blood flow response develops before recovery of the electroencephalographic amplitude (see above), suggesting that it probably reflects events other than those due to enhanced neuronal activity. Nevertheless, we cannot completely rule out the participation of glial cells or perivascular fibers at this time. 27 There are several disadvantages to the use of L-arginine in ischemia. Synthesis of NO is dependent on a complex enzymatic reaction that may not be sustained within ischemic tissue, as found recently for brain NO synthase activity (and NO levels). 28 ' 29 In fact, timedependent decreases in NO synthase activity may account for our preliminary findings showing that L-arginine treatment begun at 1 hour after MCA occlusion failed to increase blood flow or reduce infarct size (E.M, M.A.M., Z.H., T.Y., K.I., T.D., unpublished data, 1993).
Taken together, these findings suggest that NO synthesis within brain possesses features that may be unique and suggest novel strategies for improving blood flow to the brain.
